Researchers say medications commonly recommended for irritable bowel syndrome should be evaluated not just for symptom relief, but for how often side effects lead patients to stop treatment.
Renin-angiotensin system inhibitors, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, are established teratogens, whereas the teratogenicity of statins is suspected but uncertain.
Using chronological age alone to implement deprescribing is not appropriate, as many nonfrail older adults would benefit from continued antihypertensive treatment.
